BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Rinella ME, Sanyal A, Harrison SA, Brunt E, Goodman Z, Cohen DE, Loomba R. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2020;. [PMID: 32544255 DOI: 10.1002/hep.31420] [Cited by in Crossref: 47] [Cited by in F6Publishing: 57] [Article Influence: 47.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Cai BY, Zhu LX, Xin X, Wang X, An ZM, Li S, Hu YY, Feng Q. Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice. Life Sci 2020;261:118457. [PMID: 32961235 DOI: 10.1016/j.lfs.2020.118457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
3 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Nguyen VH, Le MH, Henry L, Cheung R. Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40:3145. [PMID: 32941668 DOI: 10.1111/liv.14664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Baratta F, Ferro D, Pastori D, Colantoni A, Cocomello N, Coronati M, Angelico F, Del Ben M. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. Int J Environ Res Public Health 2021;18:8993. [PMID: 34501590 DOI: 10.3390/ijerph18178993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Milic J, Barbieri S, Gozzi L, Brigo A, Beghé B, Verduri A, Bacca E, Iadisernia V, Cuomo G, Dolci G, Yaacoub D, Aprile E, Belli M, Venuta M, Meschiari M, Sebastiani G, Clini E, Mussini C, Lonardo A, Guaraldi G, Raggi P. Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome. Open Forum Infect Dis 2022;9:ofac003. [PMID: 35146047 DOI: 10.1093/ofid/ofac003] [Reference Citation Analysis]
8 Khayyat YM. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study. Physiol Rep 2021;9:e14949. [PMID: 34278728 DOI: 10.14814/phy2.14949] [Reference Citation Analysis]
9 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
10 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00719-9. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
12 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wang YZ. MAFLD supported by 95.45% participants of CSH is NOT representative. J Hepatol 2021:S0168-8278(21)00420-7. [PMID: 34153397 DOI: 10.1016/j.jhep.2021.06.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kim TH, Lee Y, Lee YS, Gim JA, Ko E, Yim SY, Jung YK, Kang S, Kim MY, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639. [PMID: 34282172 DOI: 10.1038/s41598-021-94115-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
17 González-Arceo M, Gómez-Zorita S, Aguirre L, Portillo MP. Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2017. [PMID: 34208211 DOI: 10.3390/nu13062017] [Reference Citation Analysis]
18 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
19 Alam S, Fahim SM. Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World J Hepatol 2021; 13(10): 1203-1207 [PMID: 34786161 DOI: 10.4254/wjh.v13.i10.1203] [Reference Citation Analysis]
20 [DOI: 10.1101/2020.09.23.20200535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Targher G. What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites. 2020;10. [PMID: 33049948 DOI: 10.3390/metabo10100397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, Kerling A, Eigendorf J, Kück M, Hanke AA, Ensslen R, Nachbar L, Lauenstein D, Böthig D, Hilfiker-Kleiner D, Stiesch M, Terkamp C, Wedemeyer H, Haverich A, Tegtbur U. Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol 2021;12:e00371. [PMID: 34140456 DOI: 10.14309/ctg.0000000000000371] [Reference Citation Analysis]
23 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
24 Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne) 2021;8:693507. [PMID: 34277667 DOI: 10.3389/fmed.2021.693507] [Reference Citation Analysis]
25 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
26 Liu J, Mu C, Li K, Luo H, Liu Y, Li Z. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis. Int J Public Health 2021;66:1604371. [PMID: 34690666 DOI: 10.3389/ijph.2021.1604371] [Reference Citation Analysis]
27 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
28 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
29 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Reference Citation Analysis]
30 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Reference Citation Analysis]
31 Xin X, Jin Y, Wang X, Cai B, An Z, Hu YY, Feng Q. A Combination of Geniposide and Chlorogenic Acid Combination Ameliorates Nonalcoholic Steatohepatitis in Mice by Inhibiting Kupffer Cell Activation. Biomed Res Int 2021;2021:6615881. [PMID: 34095305 DOI: 10.1155/2021/6615881] [Reference Citation Analysis]
32 Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00567-X. [PMID: 34033923 DOI: 10.1016/j.cgh.2021.05.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Karamfilova V, Assyov Y, Nedeva I, Gateva A, Ivanova I, Cherkezov N, Mateva L, Kamenov Z. Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2021. [PMID: 34818080 DOI: 10.1089/met.2021.0086] [Reference Citation Analysis]
34 Koutoukidis DA, Morris E, Henry JA, Shammoon Y, Zimmerman M, Michalopoulou M, Jebb SA, Aveyard P. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLoS One 2021;16:e0250385. [PMID: 33882107 DOI: 10.1371/journal.pone.0250385] [Reference Citation Analysis]
35 Decraecker M, Dutartre D, Hiriart JB, Irles-Depé M, Chermak F, Foucher J, de Lédinghen V. Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. Aliment Pharmacol Ther 2022. [PMID: 34978351 DOI: 10.1111/apt.16760] [Reference Citation Analysis]
36 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ignat MV, Coldea TE, Salanță LC, Mudura E. Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. Plants (Basel) 2021;10:216. [PMID: 33498684 DOI: 10.3390/plants10020216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Yang RX, Zou ZS, Zhong BH, Deng H, He FP, Shi JP, Zhao CY, Mi YQ, Zhou YJ, Di FS, Zheng RD, Du Q, Shang J, Popovic B, Chen J, Fan JG. The pathologic relevance of metabolic criteria in patients with biopsy-proven non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00112-0. [PMID: 34246549 DOI: 10.1016/j.hbpd.2021.06.002] [Reference Citation Analysis]
39 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Niriella MA, Ediriweera DS, Kasturiratne A, De Silva ST, Dassanayaka AS, De Silva AP, Kato N, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. PLoS One 2021;16:e0245762. [PMID: 33534815 DOI: 10.1371/journal.pone.0245762] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
41 Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. Front Med (Lausanne) 2021;8:781567. [PMID: 34957156 DOI: 10.3389/fmed.2021.781567] [Reference Citation Analysis]
42 Di Pasqua LG, Cagna M, Berardo C, Vairetti M, Ferrigno A. Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. Biomedicines 2022;10:194. [DOI: 10.3390/biomedicines10010194] [Reference Citation Analysis]
43 Taheri E, Pourhoseingholi MA, Moslem A, Hassani AH, Mousavi Jarrahi A, Asadzadeh Aghdaei H, Zali MR, Hatami B. The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults. J Diabetes Metab Disord. [DOI: 10.1007/s40200-021-00941-w] [Reference Citation Analysis]
44 Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021:S0168-8278(21)01964-4. [PMID: 34380057 DOI: 10.1016/j.jhep.2021.07.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
46 Wong VW, Lazarus JV. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. J Hepatol 2021:S0168-8278(21)02015-8. [PMID: 34464658 DOI: 10.1016/j.jhep.2021.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol 2020; 12(12): 1168-1181 [PMID: 33442446 DOI: 10.4254/wjh.v12.i12.1168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Reference Citation Analysis]
49 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
50 Tamaki N, Kurosaki M, Higuchi M, Izumi N. Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. Hepatol Res 2021;51:1172-3. [PMID: 34724297 DOI: 10.1111/hepr.13700] [Reference Citation Analysis]
51 Tang R, Li R, Li H, Ma XL, Du P, Yu XY, Ren L, Wang LL, Zheng WS. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease. ACS Nano 2021. [PMID: 34705426 DOI: 10.1021/acsnano.1c02158] [Reference Citation Analysis]
52 Lu CW, Lee YC, Chiang CH, Chang HH, Yang WS, Huang KC. Independent Dose-Response Associations between Fetuin-A and Lean Nonalcoholic Fatty Liver Disease. Nutrients 2021;13:2928. [PMID: 34578806 DOI: 10.3390/nu13092928] [Reference Citation Analysis]
53 Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. Gut Liver 2021;15:451-8. [PMID: 33431715 DOI: 10.5009/gnl20218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
54 Hernaez R, Peck-Radosavljevic M. MAFLD, HCC and the dilemma of (changing) terminology in liver diseases. Gut 2022:gutjnl-2022-326992. [PMID: 35169004 DOI: 10.1136/gutjnl-2022-326992] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
56 Mantovani A, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liver Dis 2020;52:1519-20. [PMID: 33012657 DOI: 10.1016/j.dld.2020.09.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
58 Mendez-sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-ferrer J, Restrepo JC, Padilla-machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology & Hepatology 2021;6:65-72. [DOI: 10.1016/s2468-1253(20)30340-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 32.0] [Reference Citation Analysis]
59 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Reference Citation Analysis]
60 Duseja A, Taneja S. Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease - Not Only Premature But Also Confusing. J Clin Exp Hepatol 2021;11:278-9. [PMID: 33746456 DOI: 10.1016/j.jceh.2020.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
62 Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible? World J Hepatol 2022; 14(1): 158-167 [DOI: 10.4254/wjh.v14.i1.158] [Reference Citation Analysis]
63 Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, Stickel F, Niederseer D, Aigner E, Datz C. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. Clin Transl Gastroenterol 2021;12:e00326. [PMID: 33821832 DOI: 10.14309/ctg.0000000000000326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
65 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Reference Citation Analysis]
66 Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34707258 DOI: 10.1038/s41575-021-00523-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Hatasa M, Yoshida S, Takahashi H, Tanaka K, Kubotsu Y, Ohsugi Y, Katagiri T, Iwata T, Katagiri S. Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response. Int J Mol Sci 2021;22:3728. [PMID: 33918456 DOI: 10.3390/ijms22073728] [Reference Citation Analysis]
68 Tsochatzis EA, Srivastava A, Rosenberg W. Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". J Hepatol 2021;74:248-9. [PMID: 32981752 DOI: 10.1016/j.jhep.2020.09.007] [Reference Citation Analysis]
69 Brodosi L, Marchignoli F, Marchesini G, Petroni ML. Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opin Pharmacother 2021;:1-5. [PMID: 34541981 DOI: 10.1080/14656566.2021.1980538] [Reference Citation Analysis]
70 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
71 Vadarlis A, Chantavaridou S, Kalopitas G, Bakaloudi DR, Karanika E, Tsekitsidi E, Chourdakis M. Τhe anthropometric and biochemical profile of pediatric non-alcoholic fatty liver disease: A systematic review and a meta-analysis. Clin Nutr 2021;41:105-21. [PMID: 34872045 DOI: 10.1016/j.clnu.2021.11.016] [Reference Citation Analysis]
72 Bianco C, Romeo S, Petta S, Long MT, Valenti L. MAFLD vs NAFLD: Let the contest begin! Liver Int 2020;40:2079-81. [PMID: 32930521 DOI: 10.1111/liv.14620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
73 Lai Y, Su C, Hung T, Yun C, Tsai C, Yeh H, Hung C. Association of Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis with Epicardial Adipose Tissue Volume and Atrial Deformation Mechanics in a Large Asian Population Free from Clinical Heart Failure. Diagnostics 2022;12:916. [DOI: 10.3390/diagnostics12040916] [Reference Citation Analysis]
74 Meadows V, Baiocchi L, Kundu D, Sato K, Fuentes Y, Wu C, Chakraborty S, Glaser S, Alpini G, Kennedy L, Francis H. Biliary Epithelial Senescence in Liver Disease: There Will Be SASP. Front Mol Biosci 2021;8:803098. [PMID: 34993234 DOI: 10.3389/fmolb.2021.803098] [Reference Citation Analysis]
75 Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, Bourke L, Simmons D, Roberts SK. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol 2021. [PMID: 34693553 DOI: 10.1111/jgh.15723] [Reference Citation Analysis]
76 Ma C, Yan K, Wang Z, Zhang Q, Gao L, Xu T, Sai J, Cheng F, Du Y. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered 2021;12:2187-202. [PMID: 34096467 DOI: 10.1080/21655979.2021.1933302] [Reference Citation Analysis]
77 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
78 Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, Chen X. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism 2021;127:154955. [PMID: 34915036 DOI: 10.1016/j.metabol.2021.154955] [Reference Citation Analysis]
79 Cataldi M, Manco F, Tarantino G. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. Int J Mol Sci 2021;22:12947. [PMID: 34884762 DOI: 10.3390/ijms222312947] [Reference Citation Analysis]
80 Guaraldi G, Milic J, Sebastiani G, Raggi P. Sarcopenic obesity at the crossroad of pathogenesis of cardiometabolic diseases. Atherosclerosis 2021;335:84-6. [PMID: 34563339 DOI: 10.1016/j.atherosclerosis.2021.09.006] [Reference Citation Analysis]
81 Lonardo A. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease. Clinical and Translational Dis 2021;1. [DOI: 10.1002/ctd2.9] [Reference Citation Analysis]
82 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
83 Guerra S, Mocciaro G, Gastaldelli A. "Adipose tissue insulin resistance and lipidome alterations are the characterizing factors of NASH". Eur J Clin Invest 2021;:e13695. [PMID: 34695228 DOI: 10.1111/eci.13695] [Reference Citation Analysis]
84 Chan WK, Wong VW. Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. Liver Int 2022;42:271-3. [PMID: 35092337 DOI: 10.1111/liv.15142] [Reference Citation Analysis]
85 Putri RR, Casswall T, Hagman E. Risk and protective factors of non-alcoholic fatty liver disease in paediatric obesity: A nationwide nested case-control study. Clin Obes 2021;:e12502. [PMID: 34873855 DOI: 10.1111/cob.12502] [Reference Citation Analysis]